Non-alcoholic fatty liver disease (NAFLD) is known to be associated with polycystic ovary syndrome (PCOS).
However, most studies investigated the prevalence of NAFLD in obese PCOS patients.
Dr Kim and colleagues from California, USA compared the prevalence of non-obese NAFLD in women with or without PCOS, and assessed an independent association between PCOS and NAFLD in a non-obese Asian cohort.
The researchers performed a case–control study using a prospective PCOS cohort.
After subjects with other potential causes of chronic liver disease were excluded, 275 non-obese women with PCOS and 892 non-obese controls were enrolled.
NAFLD was determined by hepatic ultrasonography.
|Non-obese women with PCOS had a significantly higher prevalence of NAFLD|
|Alimentary Pharmacology & Therapeutics|
The researchers' main outcomes were the prevalence of NAFLD on hepatic ultrasonography between non-obese women with or without PCOS, and an independent association between non-obese NAFLD and PCOS.
The team found that non-obese women with PCOS had a significantly higher prevalence of NAFLD than those without PCOS.
The researchers observed that PCOS was associated with non-obese NAFLD after adjustment for age and body mass index (BMI).
In women with PCOS, the level of androgenicity represented by free testosterone or free androgen index was associated with NAFLD after adjustment for age, BMI, lipid profile, insulin resistance or glycemic status.
Dr Kim's team comments, "Non-obese NAFLD is more prevalent in women with polycystic ovary syndrome than in those without."
"In non-obese patients with polycystic ovary syndrome, hyperandrogenemia may be an independent risk factor for non-obese NAFLD."